Active Not RecruitingNCT04422652
Behavioral activation and bupropion in stepwise depression care for chronic kidney disease
About this title
Read the official source — NCT04422652Medication studyAges 18+United States
Understand this study
Who could participate?
Listed age limits: from 18 years.
- Listed locations
- Stony Brook and 3 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: September 24, 2020
- Recruitment status
- Active Not Recruiting
- Enrollment listed in the registry
- 201
- Sponsor
- Stony Brook University
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Psychotherapy / behavioral intervention, Medication / drug, OTHER
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- Over 18 Years
- Official registry ID
- NCT04422652
- Official title
Show the full official title
Combination of Novel Therapies for CKD Comorbid Depression (CONCORD)
Recruitment & locations
Not recruitingThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Stony Brook · Dallas · Seattle
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Stony Brook University, a university.
Does this study involve medication?
Yes. The study involves medication, including Bupropion and Placebo.
Who can participate?
Listed age limits: from 18 years.
Is this study still recruiting?
The registry lists this study as active, but no longer recruiting.
